Literature DB >> 20488820

Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.

Jorge E Toblli1, Gabriel Cao, Leda Olivieri, Margarita Angerosa.   

Abstract

BACKGROUND: Intravenous (i.v.) iron is essential for managing haemoglobin levels in haemodialysis patients. However, i.v. iron may cause variable degrees of toxicity. This is mainly related to the pharmacological characteristics of any given i.v. iron compound.
METHODS: This blinded study examines the effects of five i.v. iron preparations on haemodynamic and functional parameters. Sixty Sprague-Dawley rats (n = 10/group) received high or low molecular weight (HMW/LMW) iron dextran, ferric gluconate (FG), ferric carboxymaltose (FCM), iron sucrose (ISC) or isotonic saline solution (control). Five i.v. doses of iron (40 mg iron/kg) or saline were administered over 4 weeks.
RESULTS: Systolic blood pressure was significantly reduced in the LMW dextran group, whereas serum iron and percentage transferrin saturation were significantly elevated in all treatment groups. Creatinine clearance was reduced and urinary protein excretion increased in the FG group only (P < 0.01). Liver enzyme levels in the blood were increased (P < 0.01) in the FG and two dextran groups compared with the FCM and ISC groups. Analysis of liver, heart and kidney homogenates showed a significant increase in catalase and malondialdehyde levels in the FG group, and an increase in CuZn-superoxide dismutase and glutathione (GSH) peroxidase activity accompanied with a decrease in the reduced-to-oxidized GSH ratio in the FG and two dextran groups (P < 0.01). Tumour necrosis factor alpha and interleukin-6 levels were significantly elevated in liver, heart and kidney samples from the FG and two dextran groups but not the FCM, ISC or control groups.
CONCLUSIONS: These findings indicate that FG and HMW/LMW iron dextran have less favourable safety profiles than FCM and ISC in normal rats.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488820     DOI: 10.1093/ndt/gfq260

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.

Authors:  Navdeep Tangri; Dana C Miskulin; Jing Zhou; Karen Bandeen-Roche; Wieneke M Michels; Patti L Ephraim; Aidan McDermott; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Bernard G Jaar; Klemens Meyer; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2014-11-02       Impact factor: 5.992

Review 2.  Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide.

Authors:  Fernando Gomollón; Javier P Gisbert
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Ferric carboxymaltose: a review of its use in iron deficiency.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

4.  Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing.

Authors:  Alina Daba; Konstantinos Gkouvatsos; Giada Sebastiani; Kostas Pantopoulos
Journal:  J Mol Med (Berl)       Date:  2012-07-31       Impact factor: 4.599

Review 5.  Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology.

Authors:  Vincenzo Bellizzi; Giuseppe Conte; Silvio Borrelli; Adamasco Cupisti; Luca De Nicola; Biagio R Di Iorio; Gianfranca Cabiddu; Marcora Mandreoli; Ernesto Paoletti; Giorgina B Piccoli; Giuseppe Quintaliani; Maura Ravera; Domenico Santoro; Serena Torraca; Roberto Minutolo
Journal:  J Nephrol       Date:  2016-08-27       Impact factor: 3.902

Review 6.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

7.  The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.

Authors:  Jorge E Toblli; Gabriel Cao; Margarita Angerosa
Journal:  J Clin Diagn Res       Date:  2015-12-01

8.  Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents.

Authors:  Torbjörn Karlsson
Journal:  ISRN Hematol       Date:  2011-10-13

9.  Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.

Authors:  Jorge Eduardo Toblli; Gabriel Cao; Leda Oliveri; Margarita Angerosa
Journal:  Inflamm Allergy Drug Targets       Date:  2012-02

10.  Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.

Authors:  Jorge E Toblli; Gabriel Cao; Margarita Angerosa
Journal:  Drug Des Devel Ther       Date:  2015-05-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.